ACUITAS THERAPEUTICS Trademark

Trademark Overview


On Monday, May 1, 2023, a trademark application was filed for ACUITAS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ACUITAS THERAPEUTICS trademark a serial number of 97915885. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Sunday, May 12, 2024. This trademark is owned by Acuitas Therapeutics, Inc.. The ACUITAS THERAPEUTICS trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, Personal, and Legal & Social Services categories with the following description:

Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, rare diseases; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, rare diseases, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascula...

Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology

Lipids used in the manufacture of cosmetics, beverages, food products and food supplements, lipid nanoparticles used in the manufacture of cosmetics, beverages, food products, and food supplements, lipid formulations used in the manufacture of cosmetics, beverages, food products, and food supplements; nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use

Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids, lipid formulations, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid na...
acuitas therapeutics

General Information


Serial Number97915885
Word MarkACUITAS THERAPEUTICS
Filing DateMonday, May 1, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateSunday, May 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, rare diseases; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, rare diseases, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, rare diseases
Goods and ServicesRegulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology
Goods and ServicesLipids used in the manufacture of cosmetics, beverages, food products and food supplements, lipid nanoparticles used in the manufacture of cosmetics, beverages, food products, and food supplements, lipid formulations used in the manufacture of cosmetics, beverages, food products, and food supplements; nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesResearch, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids, lipid formulations, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, and nucleic acid therapeutics; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, Patisiran, BNT162b2; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateTuesday, May 30, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 30, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 30, 2023
Primary Code042
First Use Anywhere DateFriday, October 18, 2013
First Use In Commerce DateFriday, October 18, 2013

International Class045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 30, 2023
Primary Code045
First Use Anywhere DateFriday, October 18, 2013
First Use In Commerce DateFriday, October 18, 2013

Trademark Owner History


Party NameAcuitas Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, B.C. V6T1W5
CA

Trademark Events


Event DateEvent Description
Thursday, May 4, 2023NEW APPLICATION ENTERED
Tuesday, May 30, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 26, 2024ASSIGNED TO EXAMINER
Friday, January 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 26, 2024NON-FINAL ACTION WRITTEN
Friday, January 26, 2024NON-FINAL ACTION E-MAILED
Tuesday, April 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 16, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 16, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, May 12, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sunday, May 12, 2024SUSPENSION LETTER WRITTEN
Sunday, May 12, 2024LETTER OF SUSPENSION E-MAILED